Lawver Teri L 4

What Happened Teri L. Lawver, a member of Altimmune's board of directors, received an award of 48,800 derivative securities reported as an acquisition (grant) on May 1, 2026. The filing reports the award at $0.00 (derivative), indicating a grant of options or similar equity-based awards as part of director compensation rather than a cash purchase.

Key Details

• Transaction date: 2026-05-01; Filing date / Period of Report: 2026-05-01 (timely filed).
• Award: 48,800 derivative securities (reported at $0.00).
• Shares owned after transaction: not specified in the filing.
• Footnotes: F1 — granted pursuant to the Company's non-employee director compensation policy. F2 — underlying shares vest in substantially equal monthly installments over the 12 months following May 1, 2026, subject to continued service.
• Transaction type code: A (award/grant of derivative securities).

Context This is a standard non-employee director compensation grant, not an open-market purchase or sale. The award vests monthly over one year, so the director will gain voting/ownership rights (if any) only as portions vest or upon exercise, depending on the award type. Such grants are common for board service and do not by themselves indicate a buy or sell signal.